Targeted drug trial for tough pancreatic cancer withdrawn before starting
NCT ID NCT07026916
Summary
This study aimed to test an experimental drug called GFH375 in people with advanced pancreatic cancer that had spread and had a specific genetic change (KRAS G12D mutation), and who had already tried other treatments. The goal was to see if the drug could shrink tumors, control the disease, and was safe. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.